Cargando…

Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer

PURPOSE: To evaluate the efficacy and safety of iodine-125 ((125)I) seeds implantation for inoperable early-stage non-small cell lung cancer (NSCLC). MATERIAL AND METHODS: PubMed, Cochrane Library, Embase, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI), and Wanfang...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Enli, Wang, Juan, Zhang, Hongtao, Zhang, Yuwei, Jia, Chenfei, Min, Xueya, Liang, Yansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170524/
https://www.ncbi.nlm.nih.gov/pubmed/34122576
http://dx.doi.org/10.5114/jcb.2021.106241
_version_ 1783702263416487936
author Chen, Enli
Wang, Juan
Zhang, Hongtao
Zhang, Yuwei
Jia, Chenfei
Min, Xueya
Liang, Yansong
author_facet Chen, Enli
Wang, Juan
Zhang, Hongtao
Zhang, Yuwei
Jia, Chenfei
Min, Xueya
Liang, Yansong
author_sort Chen, Enli
collection PubMed
description PURPOSE: To evaluate the efficacy and safety of iodine-125 ((125)I) seeds implantation for inoperable early-stage non-small cell lung cancer (NSCLC). MATERIAL AND METHODS: PubMed, Cochrane Library, Embase, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI), and Wanfang Data were searched from inception until April 2020. Data were collected concerning overall survival, short-term efficacy, and complications. Meta-analysis was performed using R software (version 3.6.3). RESULTS: Nine studies involving 308 patients were included. Meta-analysis showed that the 1-, 2-, and 3-year survival rates were 0.98% (95% CI: 0.95-0.99%), 0.83% (95% CI: 0.77-0.89%), and 0.65% (95% CI: 0.55-0.75%), respectively; short-term local control rate (LCR) and effective rates were 0.99% (95% CI: 0.98-1.00%) and 0.92% (95% CI: 0.83-0.98%), respectively; 1-, 2-, and 3-year LCRs were 0.96% (95% CI: 0.83-1.00%), 0.94% (95% CI: 0.85-0.99%), and 0.95% (95% CI: 0.76-1.00%), respectively. Sub-group analysis of the prescribed dose found that when the prescribed dose was > 120 Gy, short-term efficacy and 1-year LCR were increased significantly (p < 0.01). The incidence of bleeding, pneumothorax, and radiation lung injury was 0.14% (95% CI: 0.07-0.21%), 0.19% (95% CI: 0.11-0.28%), and 0.00% (95% CI: 0.00-0.03%), respectively. Two studies involving 106 patients compared (125)I seeds combined with chemotherapy versus chemotherapy alone for NSCLC. Results showed that compared with chemotherapy alone, (125)I seeds combined with chemotherapy could improve short-term LCR (RR = 1.34, 95% CI: 1.09-1.65%, p = 0.005) and short-term effective rate (RR = 1.49, 95% CI: 1.14-1.96%, p = 0.004). CONCLUSIONS: (125)I seeds implantation is safe and effective approach for the treatment of inoperable early-stage NSCLC, but high-quality clinical research is still needed to further confirm the findings.
format Online
Article
Text
id pubmed-8170524
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-81705242021-06-11 Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer Chen, Enli Wang, Juan Zhang, Hongtao Zhang, Yuwei Jia, Chenfei Min, Xueya Liang, Yansong J Contemp Brachytherapy Review Paper PURPOSE: To evaluate the efficacy and safety of iodine-125 ((125)I) seeds implantation for inoperable early-stage non-small cell lung cancer (NSCLC). MATERIAL AND METHODS: PubMed, Cochrane Library, Embase, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI), and Wanfang Data were searched from inception until April 2020. Data were collected concerning overall survival, short-term efficacy, and complications. Meta-analysis was performed using R software (version 3.6.3). RESULTS: Nine studies involving 308 patients were included. Meta-analysis showed that the 1-, 2-, and 3-year survival rates were 0.98% (95% CI: 0.95-0.99%), 0.83% (95% CI: 0.77-0.89%), and 0.65% (95% CI: 0.55-0.75%), respectively; short-term local control rate (LCR) and effective rates were 0.99% (95% CI: 0.98-1.00%) and 0.92% (95% CI: 0.83-0.98%), respectively; 1-, 2-, and 3-year LCRs were 0.96% (95% CI: 0.83-1.00%), 0.94% (95% CI: 0.85-0.99%), and 0.95% (95% CI: 0.76-1.00%), respectively. Sub-group analysis of the prescribed dose found that when the prescribed dose was > 120 Gy, short-term efficacy and 1-year LCR were increased significantly (p < 0.01). The incidence of bleeding, pneumothorax, and radiation lung injury was 0.14% (95% CI: 0.07-0.21%), 0.19% (95% CI: 0.11-0.28%), and 0.00% (95% CI: 0.00-0.03%), respectively. Two studies involving 106 patients compared (125)I seeds combined with chemotherapy versus chemotherapy alone for NSCLC. Results showed that compared with chemotherapy alone, (125)I seeds combined with chemotherapy could improve short-term LCR (RR = 1.34, 95% CI: 1.09-1.65%, p = 0.005) and short-term effective rate (RR = 1.49, 95% CI: 1.14-1.96%, p = 0.004). CONCLUSIONS: (125)I seeds implantation is safe and effective approach for the treatment of inoperable early-stage NSCLC, but high-quality clinical research is still needed to further confirm the findings. Termedia Publishing House 2021-05-18 2021-06 /pmc/articles/PMC8170524/ /pubmed/34122576 http://dx.doi.org/10.5114/jcb.2021.106241 Text en Copyright © 2021 Termedia https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) )
spellingShingle Review Paper
Chen, Enli
Wang, Juan
Zhang, Hongtao
Zhang, Yuwei
Jia, Chenfei
Min, Xueya
Liang, Yansong
Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer
title Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer
title_full Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer
title_fullStr Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer
title_full_unstemmed Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer
title_short Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer
title_sort analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170524/
https://www.ncbi.nlm.nih.gov/pubmed/34122576
http://dx.doi.org/10.5114/jcb.2021.106241
work_keys_str_mv AT chenenli analysisoftheefficacyandsafetyofiodine125seedsimplantationinthetreatmentofpatientswithinoperableearlystagenonsmallcelllungcancer
AT wangjuan analysisoftheefficacyandsafetyofiodine125seedsimplantationinthetreatmentofpatientswithinoperableearlystagenonsmallcelllungcancer
AT zhanghongtao analysisoftheefficacyandsafetyofiodine125seedsimplantationinthetreatmentofpatientswithinoperableearlystagenonsmallcelllungcancer
AT zhangyuwei analysisoftheefficacyandsafetyofiodine125seedsimplantationinthetreatmentofpatientswithinoperableearlystagenonsmallcelllungcancer
AT jiachenfei analysisoftheefficacyandsafetyofiodine125seedsimplantationinthetreatmentofpatientswithinoperableearlystagenonsmallcelllungcancer
AT minxueya analysisoftheefficacyandsafetyofiodine125seedsimplantationinthetreatmentofpatientswithinoperableearlystagenonsmallcelllungcancer
AT liangyansong analysisoftheefficacyandsafetyofiodine125seedsimplantationinthetreatmentofpatientswithinoperableearlystagenonsmallcelllungcancer